HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol
Issued Date
2025-12-01
Resource Type
eISSN
27134148
Scopus ID
2-s2.0-105025357659
Journal Title
Clinical and Experimental Pediatrics
Volume
68
Issue
12
Start Page
974
End Page
980
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Experimental Pediatrics Vol.68 No.12 (2025) , 974-980
Suggested Citation
Maneechai P., Ratanatharathron C., Buaboonam J., Sanpakit K. HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol. Clinical and Experimental Pediatrics Vol.68 No.12 (2025) , 974-980. 980. doi:10.3345/cep.2025.01032 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113710
Title
HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Allopurinol is widely used to prevent hyperuricemia in patients with tumor lysis syndrome. However, its use can trigger severe cutaneous adverse reactions (SCARs) with a mortality rate of approximately 11.39%. The human leukocyte antigen (HLA)–B*58:01 genotype is a major risk factor for SCARs. Although most studies to date have examined HLA–B*58:01 in Thai adults, data on pediatric patients are limited. Purpose: Here we aimed to evaluate the association between HLA-B*58:01 and skin reactions in children with hematological or oncological diagnoses receiving allo-purinol and determine its prevalence in this population. Methods: Pediatric patients (age≤18 years) with hemato-logical or oncological diseases who received allopurinol were enrolled in this cross-sectional study of previously exposed and newly prescribed cases. HLA-B*58:01 geno-typing was performed to assess its association with skin reactions. Results: A total of 108 patients (mean age, 9.3 years) were included. Most patients (n=93, 86.1%) received allopurinol as prophylaxis for tumor lysis syndrome. Of them, 75 (69.4%) received allopurinol concomitantly with chemo-therapy for malignancies, whereas the remaining patients received allopurinol during conditioning for hemato-poie tic stem cell transplantation. The prevalence of HLA–B*58:01 positivity was 17.6% (n=19 of 108 patients). The median exposure duration was 5 days (range, 1-19 days). No HLA–B*58:01–positive patients experienced a skin reaction. However, one patient who tested negative for HLA-B*58:01 developed a maculopapular rash on day 2 of the allopurinol therapy and required intravenous antihistamines. Conclusion: Short-duration allopurinol exposure likely mitigates the risk of SCARs regardless of HLA–B*58:01 status. Routine HLA-B*58:01 testing may not be warranted in pediatric patients receiving brief allopurinol courses. However, larger studies are required to confirm these findings.